Cooley And Shearman Steer Biotech Orphazyme's $84M IPO
Danish biotechnology firm Orphazyme raised $84 million on Tuesday through a U.S. initial public offering and private placement in order to fund a therapy for rare neurodegenerative diseases, advised by Cooley LLP...To view the full article, register now.
Already a subscriber? Click here to view full article